SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models

SGN-CD228A is an investigational antibody–drug conjugate (ADC) directed to melanotransferrin (CD228, MELTF, MFI2, p97), a cell-surface protein first identified in melanoma. SGN-CD228A consists of a humanized antibody, hL49, with high specificity and affinity for CD228 that is stably conjugated to 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazahreh, Rebecca, Mason, Marsha L., Gosink, John J., Olson, Devra J., Thurman, Robert, Hale, Christopher, Westendorf, Lori, Pires, Thomas A., Leiske, Christopher I., Carlson, Markus, Nguyen, Liem T., Cochran, Julia H., Okeley, Nicole M., Yumul, Roma, Jin, Steven, Stone, Ivan J., Sahetya, Disha, Nesterova, Albina, Allred, Sean, Hensley, Kelly M., Hu, Rachael, Lawrence, Robert, Lewis, Timothy S., Sandall, Sharsti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068445/
https://www.ncbi.nlm.nih.gov/pubmed/36800443
http://dx.doi.org/10.1158/1535-7163.MCT-22-0401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068445/
https://www.ncbi.nlm.nih.gov/pubmed/36800443
http://dx.doi.org/10.1158/1535-7163.MCT-22-0401

Ejemplares similares